PlainPharmaWatch

CMS Open Payments · Program Year 2024

Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. reported $5,489.18 across General Payments, Research, and Ownership to 214 physicians and teaching hospitals across 214 transactions.

See the rankings → How this is sourced
$5.5K
All-tracks total
214
Transactions
214
Recipients
#1704
of 1,925 companies

Aquestive Therapeutics, Inc. reported $5,489.18 across all CMS Open Payments tracks (General + Research + Ownership) to 214 physicians and teaching hospitals in Program Year 2024 - ranking #1704 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $5,489.18, averaging $25.65 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer aquestive-therapeutics-inc Aquestive Therapeutics, Inc.

$5.5K · #1704/1,925 · 0.0% industry · PY2024

  • TOT $5.5K
  • RANK #1704
  • SHARE 0.0%
  • TXN 214
  • RCP 214
  • CAT 1
  • GEN $5.5K
  • TOP1 1.9%
  • PY 2024

Volume peers

Nearest volume peer: Granata Bio Corporation ($5.5K)

Bridge to Life Ltd$5.6KRare Disease Therapeutics, I…$5.6KKarl Storz Endovision, Inc.$5.5KGranata Bio Corporation$5.5KAquestive Therapeutics, Inc.…$5.5K
All-tracks payment totals near Aquestive Therapeutics, Inc. (CMS Open Payments PY2024)

Aquestive Therapeutics, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

What the Data Shows for Aquestive Therapeutics, Inc.

Rank #1704 of 1,925 companies in CMS Open Payments for 2024 belongs to Aquestive Therapeutics, Inc., which reported $5,489.18 across 214 transactions to 214 recipients - a comparatively small 0.0% slice of all industry payments reported nationwide for the year. Averages work out to $25.65 per transaction and $25.65 per recipient.

The 1-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Food and Beverage" at $5.5K, accounting for 100.0% of this company's General Payments and 214 transactions.

General Payment Breakdown by Type

"Food and Beverage" leads Aquestive Therapeutics, Inc.'s 1-category general-payment breakdown at $5.5K, 100.0% of the reported total.

How Aquestive Therapeutics, Inc. divides its payments

Ranked by total dollars reported per category

1. Food and Beverage$5.5K
Payment Type Amount Transactions
Food and Beverage $5.5K 214

Recipient Concentration in General Payments

The five largest recipient relationships account for $496.85 (9.1%) of $5,489.18 in this company's General Payments records across 178 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Aquestive Therapeutics, Inc.

The five named recipients with the highest reported General Payments from this company

Vivek U Rao$103.38Sonali P Majmudar$103.38Lukena Ulhas Karkhanis$103.37Dana Wallace$103.37Mahendra Dadhania$83.35
  1. 1

    Vivek U Rao

    $103.38 across 1 reported transactions

  2. 2

    Sonali P Majmudar

    $103.38 across 1 reported transactions

  3. 3

    Lukena Ulhas Karkhanis

    $103.37 across 1 reported transactions

  4. 4

    Dana Wallace

    $103.37 across 1 reported transactions

  5. 5

    Mahendra Dadhania

    $83.35 across 1 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Aquestive Therapeutics, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Aquestive Therapeutics, Inc..

Notal Vision, Inc.

HHI 81

Atricure, Inc.

HHI 80

Tris Pharma Inc

HHI 83

Spinal Elements, Inc.

HHI 83

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Aquestive Therapeutics, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Aquestive Therapeutics, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.